 Home > Medical News > Latest Medical News > Ocular terminates cooperation with Regeneron to develop aflibercept sustained-release formulations

Ocular terminates cooperation with Regeneron to develop aflibercept sustained-release formulations

 Last Update: 2021-09-05
 Source: Internet
 Author: User

Tags

drug patent expiration database

brovana drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compiler: Fan Dongdong

A few days ago, Ocular Therapeutix and Regeneron announced the termination of their cooperation and the suspension of the development of aflibercept sustained-release preparations for the treatment of wet age-related macular degeneration (AMD) and other serious retinal diseases.
The decision to terminate will take effect on August 5, 2021.

.

Ocular is a biopharmaceutical company specializing in the formulation, development and commercialization of innovative treatments for ocular diseases and disorders.
In 2016, the company and Regeneron launched an ocular treatment cooperation
.

According to the cooperation agreement, Regeneron will use Ocular's hydrogel technology to develop and commercialize aflibercept and other targeted VEGF drug sustained-release formulations for ophthalmic indications

Antony Mattessich, President and CEO of Ocular Therapeutix said, “Although I regret the end of the cooperation, Ocular is very grateful for the opportunity to cooperate with Regeneron to develop aflibercept
.

This cooperation may bring valuable strategic driving force for Ocular's future product lines.

As a VEGF inhibitor, aflibercept can block the growth of new blood vessels by blocking VEGF-A and placental growth factor (PLGF), two growth factors involved in angiogenesis, and reduce the ability of fluid to pass through blood vessels (vascular permeability).

)

It is worth noting that aflibercept injection formulation is about to face the challenge of patent expiration in 2025
.

Currently, the main competitor of the drug in the market is Novartis Beovu (brolucizumab)

Reference source: Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.